European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading

MT Newswires Live09-18

European equities traded in the US as American depositary receipts were edging lower late Wednesday morning, declining 0.18% to 1,435.51 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company argenx (ARGX) and telecommunications operator Telefonica (TEF), which rose 1.2% and 0.9% respectively. They were followed by biopharmaceutical company Calliditas Therapeutics (CALT) and financial services company Banco Bilbao Vizcaya Argentaria (BBVA), which were up 0.7% and 0.4% respectively.

The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and telecommunications operator VEON (VEON), which fell 4.4% and 2.9% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company DBV Technologies (DBVT), which were down 2.3% and 1.6% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Autolus Therapeutics (AUTL), which advanced 8.1% and 2.6% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and cruise line operator Carnival (CUK), which increased 2.7% and 2.1% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies TC Biopharm (TCBP) and NuCana (NCNA), which dropped 4.7% and 1.9% respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which lost 3.4% and 1.2% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment